Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial

The Lancet

Volumn 379, Issue 9825, 2012, Pages 1498-1507

  Garber, Alan J ^a   King, Allen B ^b   Del Prato, Stefano ^c   Sreenan, Seamus ^d   Balci, Mustafa K ^e   Muñoz Torres, Manuel ^f   Rosenstock, Julio ^g   Endahl, Lars A ^h   Ocampo Francisco, Ann Marie ^h   Hollander, Priscilla ⁱ  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Diabetes Care Center   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d Stroke and Hypertension Unit   (Ireland)

^e AKDENIZ UNIVERSITY   (Turkey)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^g Dallas Diabetes and Endocrine   (United States)

^h NOVO NORDISK A S   (Denmark)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLEXPEN; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84859921058     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60205-0     Document Type: Article

References (28)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12.
2. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002; 45: 937-48.
3. Jonassen I, Havelund S, Ribel U, et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes 2010; 59: A11.
4. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Haahr H. The pharmacodynamic variability of insulin degludec is consistently lower than insulin glargine over 24 hours at steady state. Diabetes 2011; 60: A263.
5. Heise T, Hovelmann U, Nosek L, Bottcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes 2011; 60: LB11.
6. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-longacting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011; 377: 924-31.
7. ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med 2001; 47: 199-203.
8. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 2009; 107: 403-05.
9. Workgroup on Hypoglycemia/American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-49.
10. Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. User's manual for the SF-36v2 health survey, 2nd edn. Lincoln, RI, USA: QualityMetric Incorporated, 2007.
11. Guidance for Industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ ucm071624.pdf (accessed March 19 2010).
12. Banarer S, Cryer PE. Hypoglycemia in type 2 diabetes. Med Clin North Am 2004; 88: 1107-16.
13. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 240: b4909.
14. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363: 1410-18.
15. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011; 34 (suppl 2): S132-37.
16. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 2011; 34: 1164-70.
17. Robinson RT, Harris ND, Ireland RH, Less S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes 2003; 52: 1469-74.
18. Riddle MC. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 1989; 12: 623-29.
19. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-86.
20. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; 6: CD006383.
21. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-74.
22. Nakar S, Yitzhaki G, Rosenberg R, Vinker S. Transition to insulin in type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications 2007; 21: 220-26.
23. Cuddihy RM, Philis-Tsimikas A, Nazeri A. Type 2 diabetes care and insulin intensification: is a more multidisciplinary approach needed? Results from the MODIFY survey. Diabetes Educ 2011; 37: 111-23.
24. Frier BM. How hypoglycaemia can aff ect the life of a person with diabetes. Diabetes Metab Res Rev 2008; 24: 87-92.
25. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 9: 363-70.
26. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications 2004; 18: 60-68.
27. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on diabetes management and work productivity. Value Health 2011; 14: 665-71.
28. Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two diff erent fasting plasma glucose targets\the TITRATE study. Diabetes Obes Metab 2009; 11: 623-31.